Columbia University scientists developed a two-step RNA therapy that may repair cardiovascular tissue after a heart attack by ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

The U.S. FDA appears poised to allow compounding pharmacies to again sell injectable peptides, a class of products with ...

Social media influencers tout the benefits — from weight loss to collagen production to pain reduction — and direct followers to websites to buy peptides.

Though lab-made peptides are touted as a cure-all, they are not FDA-regulated and pose serious risks, experts warn ...

Oral GLP-1 receptor agonists are generating a great deal of excitement as a potential inflection point in diabetes and ...

CLEVELAND, Ohio — A recent clinical trial led by the University of Cincinnati looked at whether people living with HIV were ...

Model estimates SUBLOCADE ® may reduce staff time and associated costs compared with other medications for opioid use disorder in jails and prisons ; RICHMOND, Va., March 31, 202 ...

Oral GLP-1 vs injection: which works better? Experts explain why injections still lead in weight loss—and how new oral ...

The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...

The latest wellness craze to take social media by storm is fuelling a growing grey market of injectable peptides in Australia, and it has experts worried.

Ottawa , Feb. 18, 2025 (GLOBE NEWSWIRE) -- The global injectable drug delivery devices market size was valued at USD 519 billion in 2024 and is expected to hit around USD 1,217 billion by 2034, a ...